Pfizer Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (400)

Latest Posts

About This Stock More About This Stock
Exact Sciences: Poised For Further Growth
Article By: TipRanks
Sunday, November 4, 2018 3:17 PM EST
Exact Sciences is moving forward on a solid foundation: a proven product, a new marketing initiative to expand – or even double – its reach. It’s no surprise that every analyst who has reviewed EXAS recently has given it a ‘Buy’ rating
In this article: PFE, EXAS
A Drug Giant Whose Dividend Safety Isn’t As Bad As It Looks
Article By: Marc Lichtenfeld
Wednesday, October 10, 2018 7:30 PM EST
Investors tend to buy large pharmaceutical companies because of their safety.
In this article: PFE
AI And The New Health Care
Article By: John Thomas
Friday, September 28, 2018 3:34 AM EST
The first major industry to be fundamentally disrupted by AI will be health care. The next step in our intellectual evolution will be carried out by AI. By connecting our neocortex to the Internet, we will greatly improve our intelligence.
In this article: BMY, MRK, PFE, XLV, XPH
Week In Review: Three More China Biopharmas Planning Hong Kong IPOs
Article By: ChinaBio® Today
Saturday, August 25, 2018 4:14 PM EST
Mabpharm Limited, a Taizhou biotech, will IPO in Hong Kong, the eleventh pre-revenue China biopharma to be approved to list there. Mabpharm is developing a portfolio of nine biosimilars, which it hopes will prove to be biobetters.
In this article: BNY, PFE, CBPO, BGNE, ZLAB
Pfizer Beats On Q2 Earnings & Sales, Ups Profit View
Article By: Zacks Investment Research
Tuesday, July 31, 2018 10:49 AM EST
Pfizer, Inc. reported second-quarter 2018 adjusted earnings per share of 81 cents.
In this article: PFE Also: JNJ, MRK, AMGN


Latest Tweets for $PFE

No tweets yet!


Exact Sciences: Poised For Further Growth
James Dean Samuels 11/22/2018 6:59:36 PM

Great article! Analyst consensus = strong buy with $90 price target. $PFE $EXAS

1 to 1 of 1 comments